Literature DB >> 19401681

Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia.

J K Yao1, G G Dougherty, R D Reddy, M S Keshavan, D M Montrose, W R Matson, S Rozen, R R Krishnan, J McEvoy, R Kaddurah-Daouk.   

Abstract

Schizophrenia is characterized by complex and dynamically interacting perturbations in multiple neurochemical systems. In the past, evidence for these alterations has been collected piecemeal, limiting our understanding of the interactions among relevant biological systems. Earlier, both hyper- and hyposerotonemia were variously associated with the longitudinal course of schizophrenia, suggesting a disturbance in the central serotonin (5-hydroxytryptamine (5-HT)) function. Using a targeted electrochemistry-based metabolomics platform, we compared metabolic signatures consisting of 13 plasma tryptophan (Trp) metabolites simultaneously between first-episode neuroleptic-naive patients with schizophrenia (FENNS, n=25) and healthy controls (HC, n=30). We also compared these metabolites between FENNS at baseline (BL) and 4 weeks (4w) after antipsychotic treatment. N-acetylserotonin was increased in FENNS-BL compared with HC (P=0.0077, which remained nearly significant after Bonferroni correction). N-acetylserotonin/Trp and melatonin (Mel)/serotonin ratios were higher, and Mel/N-acetylserotonin ratio was lower in FENNS-BL (all P-values<0.0029), but not after treatment, compared with HC volunteers. All three groups had highly significant correlations between Trp and its metabolites, Mel, kynurenine, 3-hydroxykynurenine and tryptamine. However, in the HC, but in neither of the FENNS groups, serotonin was highly correlated with Trp, Mel, kynurenine or tryptamine, and 5-hydroxyindoleacetic acid (5HIAA) was highly correlated with Trp, Mel, kynurenine or 3-hydroxykynurenine. A significant difference between HC and FENNS-BL was further shown only for the Trp-5HIAA correlation. Thus, some metabolite interactions within the Trp pathway seem to be altered in the FENNS-BL patients. Conversion of serotonin to N-acetylserotonin by serotonin N-acetyltransferase may be upregulated in FENNS patients, possibly related to the observed alteration in Trp-5HIAA correlation. Considering N-acetylserotonin as a potent antioxidant, such increases in N-acetylserotonin might be a compensatory response to increased oxidative stress, implicated in the pathogenesis of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19401681      PMCID: PMC2953575          DOI: 10.1038/mp.2009.33

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  75 in total

1.  Metabolomic analysis and signatures in motor neuron disease.

Authors:  Steve Rozen; Merit E Cudkowicz; Mikhail Bogdanov; Wayne R Matson; Bruce S Kristal; Chris Beecher; Scott Harrison; Paul Vouros; Jimmy Flarakos; Karen Vigneau-Callahan; Theodore D Matson; Kristyn M Newhall; M Flint Beal; Robert H Brown; Rima Kaddurah-Daouk
Journal:  Metabolomics       Date:  2005       Impact factor: 4.290

2.  Acute dietary tryptophan depletion: effects on schizophrenic positive and negative symptoms.

Authors:  R P Sharma; L E Shapiro; S K Kamath; E A Soll; M D Watanabe; J M Davis
Journal:  Neuropsychobiology       Date:  1997       Impact factor: 2.328

3.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

4.  Increased cortical kynurenate content in schizophrenia.

Authors:  R Schwarcz; A Rassoulpour; H Q Wu; D Medoff; C A Tamminga; R C Roberts
Journal:  Biol Psychiatry       Date:  2001-10-01       Impact factor: 13.382

5.  Platelet serotonin levels in schizophrenia: relationship to race and psychopathology.

Authors:  H Jackman; D Luchins; H Y Meltzer
Journal:  Biol Psychiatry       Date:  1983-08       Impact factor: 13.382

6.  Protective effect of N-acetyl-serotonin on the nonenzymatic lipid peroxidation in rat testicular microsomes and mitochondria.

Authors:  Mariana B Gavazza; Angel Català
Journal:  J Pineal Res       Date:  2004-10       Impact factor: 13.007

Review 7.  Membrane phospholipids and cytokine interaction in schizophrenia.

Authors:  Jeffrey K Yao; Daniel P van Kammen
Journal:  Int Rev Neurobiol       Date:  2004       Impact factor: 3.230

8.  A multidimensional approach to analysis of cerebrospinal fluid biogenic amines in schizophrenia: I. Comparisons with healthy control subjects and neuroleptic-treated/unmedicated pairs analyses.

Authors:  F Issa; G A Gerhardt; J J Bartko; R L Suddath; M Lynch; P H Gamache; R Freedman; R J Wyatt; D G Kirch
Journal:  Psychiatry Res       Date:  1994-06       Impact factor: 3.222

Review 9.  From membrane phospholipid defects to altered neurotransmission: is arachidonic acid a nexus in the pathophysiology of schizophrenia?

Authors:  P D Skosnik; J K Yao
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2003-12       Impact factor: 4.006

10.  Melatonin stimulates brain glutathione peroxidase activity.

Authors:  L R Barlow-Walden; R J Reiter; M Abe; M Pablos; A Menendez-Pelaez; L D Chen; B Poeggeler
Journal:  Neurochem Int       Date:  1995-05       Impact factor: 3.921

View more
  43 in total

1.  3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.

Authors:  Ruth Condray; George G Dougherty; Matcheri S Keshavan; Ravinder D Reddy; Gretchen L Haas; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk; Jeffrey K Yao
Journal:  Int J Neuropsychopharmacol       Date:  2011-01-28       Impact factor: 5.176

2.  Metabolomic changes in autopsy-confirmed Alzheimer's disease.

Authors:  Rima Kaddurah-Daouk; Steve Rozen; Wayne Matson; Xianlin Han; Christine M Hulette; James R Burke; P Murali Doraiswamy; Kathleen A Welsh-Bohmer
Journal:  Alzheimers Dement       Date:  2010-11-13       Impact factor: 21.566

Review 3.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

Review 4.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

5.  Are Uric Acid Levels Different from Healthy Subjects in Bipolar Affective Disorder and Schizophrenia?: Relationship Between Clinical Improvement and Episode Severity in Male Patients.

Authors:  Bülent Kadri Gültekin; Sermin Kesebir; Sevgi Gül Kabak; Ferzan Fikret Ergün; Elif Tatlidil Yaylaci
Journal:  Noro Psikiyatr Ars       Date:  2014-09-01       Impact factor: 1.339

6.  Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics.

Authors:  Y Ji; S Hebbring; H Zhu; G D Jenkins; J Biernacka; K Snyder; M Drews; O Fiehn; Z Zeng; D Schaid; D A Mrazek; R Kaddurah-Daouk; R M Weinshilboum
Journal:  Clin Pharmacol Ther       Date:  2010-11-24       Impact factor: 6.875

7.  Applications of cold temperature stress to age fractionate Caenorhabditis elegans: a simple inexpensive technique.

Authors:  James D Willett; Neeraja Podugu; Gita Sudama; John J Kopecky; Jenefir Isbister
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-03-30       Impact factor: 6.053

8.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

Review 9.  Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications.

Authors:  Giuseppe Fanciulli; Rosaria M Ruggeri; Erika Grossrubatscher; Fabio Lo Calzo; Troy D Wood; Antongiulio Faggiano; Andrea Isidori; Annamaria Colao
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

10.  Tryptophan Metabolism and White Matter Integrity in Schizophrenia.

Authors:  Joshua Chiappelli; Teodor T Postolache; Peter Kochunov; Laura M Rowland; S Andrea Wijtenburg; Dinesh K Shukla; Malle Tagamets; Xiaoming Du; Anya Savransky; Christopher A Lowry; Adem Can; Dietmar Fuchs; L Elliot Hong
Journal:  Neuropsychopharmacology       Date:  2016-05-04       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.